Leucocytes Identified by Automated Digital Morphology System
|
By LabMedica International staff writers Posted on 31 Oct 2013 |

Image: CellaVision DM96 Digital Cell Morphology System (Photo courtesy of CellaVision).
An automated digital cell morphology analyzer for determining leukocyte differential counts in peripheral blood smears (PBS) has been evaluated in a clinical laboratory.
The differential counting of peripheral blood leukocytes is one of the most frequently ordered laboratory tests by clinicians as it is an important test for the diagnosis of various hematologic diseases and systemic diseases. Improvements in laboratory technologies have benefited from the development of automated blood cell counters that have begun to replace the manual microscopic counting that is still performed in most laboratories.
Laboratory scientists at the University of Ulsan College of Medicine and Asan Medical Center (Seoul, Republic of Korea) examined a total of 308 peripheral blood samples with quantitative or qualitative abnormalities, for which complete blood counts had been ordered by clinicians. These samples were initially analyzed using the automatic blood cell analyzer Sysmex XE-2100 (Sysmex; Kobe, Japan), and the total leukocyte and differential counts were determined. Manual microscopic differential counts of 100 cells on each slide were separately performed by two independent well-trained laboratory technologists.
The slides were labeled and loaded into the CellaVision DM96 system (CellaVision AB; Lund, Sweden) after manual microscopic differential counting. In cases with a buffy coat preparation, the slides were prepared using samples prior to buffy coat preparation and labeled in the CellaVision DM96 system To evaluate the clinical relevance of the extension of cell counts up to 300 or 500 cells, which is the provided function by the CellaVision DM96 system, in the samples with low leukocyte count of less than 1,000 cells/μL, correlation analysis between the CellaVision DM96 system and manual count was performed.
The correlation coefficients between two methods were consistently high, ranged from 0.864 to 0.992. The sensitivity, specificity, positive predictive value, negative predictive values of this system for the identification of abnormalities was consistently high, especially for blast cells. When the instrument was instructed to count 300 or 500 cells from the operator, better performance was demonstrated than 100 cells in the leukopenic samples by sacrificing only 40 seconds/slide on average.
The authors concluded that the CellaVision DM96 system is useful in the clinical laboratory providing comparative accuracy compared with manual counts in samples with abnormalities. In leukopenic samples, report quality can be improved by ordering to count 300 or 500 cells from the operator without severe prolongation of turnaround time. The study was published on the October 2013 issue of the International Journal of Laboratory Hematology .
Related Links:
University of Ulsan College of Medicine and Asan Medical Center
Sysmex
CellaVision AB
The differential counting of peripheral blood leukocytes is one of the most frequently ordered laboratory tests by clinicians as it is an important test for the diagnosis of various hematologic diseases and systemic diseases. Improvements in laboratory technologies have benefited from the development of automated blood cell counters that have begun to replace the manual microscopic counting that is still performed in most laboratories.
Laboratory scientists at the University of Ulsan College of Medicine and Asan Medical Center (Seoul, Republic of Korea) examined a total of 308 peripheral blood samples with quantitative or qualitative abnormalities, for which complete blood counts had been ordered by clinicians. These samples were initially analyzed using the automatic blood cell analyzer Sysmex XE-2100 (Sysmex; Kobe, Japan), and the total leukocyte and differential counts were determined. Manual microscopic differential counts of 100 cells on each slide were separately performed by two independent well-trained laboratory technologists.
The slides were labeled and loaded into the CellaVision DM96 system (CellaVision AB; Lund, Sweden) after manual microscopic differential counting. In cases with a buffy coat preparation, the slides were prepared using samples prior to buffy coat preparation and labeled in the CellaVision DM96 system To evaluate the clinical relevance of the extension of cell counts up to 300 or 500 cells, which is the provided function by the CellaVision DM96 system, in the samples with low leukocyte count of less than 1,000 cells/μL, correlation analysis between the CellaVision DM96 system and manual count was performed.
The correlation coefficients between two methods were consistently high, ranged from 0.864 to 0.992. The sensitivity, specificity, positive predictive value, negative predictive values of this system for the identification of abnormalities was consistently high, especially for blast cells. When the instrument was instructed to count 300 or 500 cells from the operator, better performance was demonstrated than 100 cells in the leukopenic samples by sacrificing only 40 seconds/slide on average.
The authors concluded that the CellaVision DM96 system is useful in the clinical laboratory providing comparative accuracy compared with manual counts in samples with abnormalities. In leukopenic samples, report quality can be improved by ordering to count 300 or 500 cells from the operator without severe prolongation of turnaround time. The study was published on the October 2013 issue of the International Journal of Laboratory Hematology .
Related Links:
University of Ulsan College of Medicine and Asan Medical Center
Sysmex
CellaVision AB
Latest Hematology News
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read moreMolecular Diagnostics
view channel
Multi-Cancer Early Detection Blood Test Increases Cancer Detection
Cancer is the second leading cause of death worldwide as most deadly cancers are found too late. Approximately 70% of cancer deaths come from cancers that do not have standard-of-care screening and are... Read more
Portable Label-Free Device Tracks Alzheimer's Disease in Real Time
Alzheimer’s disease is marked by the accumulation of toxic protein fragments in the brain that damage nerve cells and impair memory. Detecting and tracking these early changes remains a major challenge,... Read moreImmunology
view channel
Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more
Luminescent Probe Measures Immune Cell Activity in Real Time
The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more
Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read moreMicrobiology
view channel
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
Sepsis is a life-threatening condition that occurs when the body’s response to infection spirals out of control, damaging organs and leading to critical illness. Patients often arrive at intensive care... Read morePathology
view channel
AI Improves Cervical Cancer Screening in Low-Resource Settings
Access to cervical cancer screening in low- and middle-income countries remains limited, leaving many women without early detection for this life-threatening disease. The lack of access to laboratories,... Read more
New Multi-Omics Tool Illuminates Cancer Progression
Tracking how cancers evolve into more aggressive and therapy-resistant forms has long been a challenge for researchers. Many current tools can only capture limited genetic information from tumor samples,... Read moreTechnology
view channel
Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
Rapid and sensitive detection of small extracellular vesicles (sEVs)—key biomarkers in cancer and organ health monitoring—remains challenging due to the need for multiple preprocessing steps and bulky... Read more
AI Algorithm Assesses Progressive Decline in Kidney Function
Chronic kidney disease (CKD) affects more than 700 million people worldwide and remains a major global health challenge. The condition often progresses silently, and many patients remain undiagnosed until... Read more
Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum
Influenza is one of the most dangerous infectious diseases worldwide, claiming around half a million lives each year. What makes it particularly insidious is that flu viruses are contagious even before... Read more
3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection
Early-stage disease diagnosis depends on the ability to detect biomarkers with exceptional sensitivity and precision. However, traditional biosensing technologies struggle with achieving this at the micro-scale,... Read moreIndustry
view channel
Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
Bio-Rad Laboratories (Hercules, CA, USA) and Biodesix (Louisville, CO, USA) have expanded their partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory... Read moreHologic to be Acquired by Blackstone and TPG
Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more







